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Abstract
Background: As cystic neoplasms of the pancreas are discovered with advanced imaging techniques,
pancreatic surgeons often struggle with identifyingwho is at risk of having or developing pancreatic cancer.
We sought to review our experience with the surgical management of cystic neoplasms of the pancreas to
determine pre-operative clinical indicators of malignancy or premalignant (i.e. mucinous) lesions.
Methods: Between 1996 and 2007, 114 consecutive patients with cystic neoplasms of the pancreas
underwent a pancreatectomy. Invasive adenocarcinoma was identified in 35 whereas 79 had benign
lesions. Mucinous lesions were considered premalignant and consisted of 29 intraductal papillary muci-
nous neoplasms (IPMN) and 17 mucinous cystic neoplasms (MCN). The remaining 33 benign lesions were
serous microcystic adenomas. Descriptive statistics were calculated and multivariate logistic regression
was performed. Receiver-operating characteristic (ROC) curves were constructed for continuous vari-
ables and the area under the curves compared. Likelihood ratios were calculated from the combinations
of predictors.
Results: Patients with pancreatic cancer arising from a cystic neoplasm were older than those with
benign cysts. Mucinous lesions with or without associated cancer were more likely to be symptomatic
and present with elevated serum carbohydrate antigen (CA)19-9 levels. Cancers more commonly pre-
sented in the head of the pancreas and were associated with longer hospitalizations after resection. Using
multivariate logistic regression, size and elevated CA19-9 were predictors of malignancy whereas male
gender and size were predictors of mucinous lesions with or without malignancy. Size, however, was not
an accurate test to determine premalignant or malignant lesions using area under the ROC curve analysis
whereas CA19-9 performed the best regardless of gender or lesion location.
Conclusions: Based upon our single institution experience with resection of cystic neoplasms of the
pancreas, we advocate an aggressive surgical approach to any patient with a cystic neoplasm of the
pancreas and associated elevated CA19-9.
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Introduction
Cystic neoplasms of the pancreas include serous cystadenomas or
serous microcystic adenomas (SMA), mucinous cystic neoplasms
(MCN) and intraductal papillary mucinous neoplasms (IPMN).
First described in the 1990s, mucinous lesions (i.e. MCN, IPMN)
represent premalignant neoplasms capable of transforming into
invasive adenocarcinoma with subsequent poor prognosis. As
cystic neoplasms of the pancreas are more commonly discovered
with advanced imaging techniques, pancreatic surgeons are often
faced with the daunting task of determining who should or,
perhapsmore difficult,who should not undergo a pancreatectomy.
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Radiographical characteristics alone are notoriously inaccurate in
predicting malignant potential of cystic pancreatic neoplasms.1
Endoscopic ultrasound with fine-needle aspiration (EUS-FNA)
and cyst fluid analysis for mucin, cellular atypia and carcinoem-
bryologic antigen (CEA) hold promise in identifying those lesions
with malignant potential.2–4 Utilization of EUS is not always fea-
sible, particularly in rural areas where many initial assessments of
pancreatic cystic neoplasms aremade.Limitations in availability or
means of accessing EUS,5,6 mean clinicians must rely on non-
invasive techniques of assessing risk of pancreatic cancer.
SMA is the most common pancreatic cystic neoplasm, repre-
senting more than 30% of all cystic neoplasms.7,8 Similar to pan-
creatic cancers, SMAs present in the 5th–7th decade of life. These
lesions are typically located in the body and tail of the pancreas
but can arise throughout the pancreatic parenchyma and may be
confused with cancerous lesions on pre-operative imaging, par-
ticularly if there is a solid component.9,10 Although these lesions
are often indolent, particularly when small (<4 cm), and carry
virtually no risk of malignant transformation, surgery is generally
recommended for those patients who are symptomatic or have
larger lesions (>4 cm), with an excellent prognosis with regards to
mortality and disease-free survival.11,12
In contradistinction from their serous counterparts, mucin-
producing cystic neoplasms are consideredpremalignant andoften
present after malignant transformation has already occurred.12,13
The two sub-types of MCNand IPMNhave distinct characteristics
and presentations. While MCNs are almost exclusively found in
women,predominantly in thebody and tail of thepancreas, IPMNs
are more common in men and typically located in the head of the
pancreas.14–16 Surgery is recommended for all patients suspected of
havingMCNwho are suitable surgical candidates as pre-operative
assessment of associated malignancy is not reliable as well as the
potential for futuremalignant transformation.12Main duct IPMNs
are similarly recommended toundergo surgical resection for risk of
occult or future malignancy.17
As an institution that, until recently, did not have ready access
to EUS, most treatment decisions regarding resection for cystic
neoplasms of the pancreas were based upon non-invasive clinical
characteristics. It is for this reason that we sought to review our
experience with the surgical management of these cystic lesions to
determine pre-operative indicators of malignancy or premalig-
nant (i.e. mucinous) lesions.
Methods
After approval by the Institutional Review Board at the Ohio State
University, the charts of 114 consecutive patients who presented to
our institution with cystic neoplasms of the pancreas and subse-
quently underwent pancreatectomy between 1996 and 2007 were
reviewed. Our criteria for resection were generally based on loca-
tion of tumour, size, tumour markers and the presence of symp-
toms. Clinicopathological characteristics such as age, gender,
clinical presentation, tumour markers, location of tumour and
size of tumour were reviewed and compared using anova or
Student’s t-tests for continuous variables and c2 or Fisher’s exact
tests for categorical data. First, benign lesions (SMA and prema-
lignant mucinous tumours) were compared with those lesions
harbouring malignancy and the descriptive statistics of sensitivity,
specificity, positive predictive value (PPV) and negative predictive
value (NPV) were calculated for each variable or combinations of
variables. A multivariate logistic regression was then performed to
identify predictors associated with malignancy. Next, SMAs were
compared with mucinous lesions with and without associated
malignancy and descriptive statistics were tabulated. Multivariate
logistic regression analysis was again undertaken to identify pre-
dictors of premalignancy and malignancy. In other words, an
attempt was made to identify predictors of the need for surgical
resection. Receiver-operating characteristic (ROC) curves were
created, and the area under the ROC curves was calculated for the
continuous variable of age, pre-operative carbohydrate antigen
(CA)19-9 and lesion size. Likelihood ratios (both positive and
negative) were calculated for the same dataset to determine the
post-resection probability of premalignancy and malignancy
based on the predictors in question. Statistical analyses were com-
pleted using SPSS vs. 17.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patient characteristics
Out of the 114 patients who underwent pancreatectomy for cystic
lesions, invasive adenocarcinoma was identified in 35, whereas 79
had benign (i.e. adenoma or borderline) lesions. The 46 mucinous
lesions were considered premalignant and consisted of 29 IPMNs
and 17 MCNs. The remaining 33 benign lesions were SMAs.
Malignant lesions tended to be diagnosed in older patients,
whereas SMAs were more common in women (Table 1). SMAs
were less likely to present with symptoms. Pain was the most
common presenting complaint in benign lesions, whereas
obstructive jaundice was associated more commonly with malig-
nant lesions. CA19-9 was rarely elevated in serous lesions but was
six times more likely to be elevated in association with mucinous
lesions and nearly 10 times more likely to be elevated when a
malignancy was present. Cystic neoplasms associated with malig-
nancy were more commonly located in the head of the pancreas,
whereas they were more likely to be in the body or tail of the
pancreas in benign lesions. Finally, the median size of all resected
lesions was 4 cm and significantly different in serous,mucinous or
malignant neoplasms.
The median hospitalization was 9 days for all patients; it was
longest in those who had an associated malignancy and shortest in
those with serous neoplasms (Table 1). Commensurate with
length of stay, complications were less common after a pancreate-
ctomy for serous lesions, although not statistically significant. A
pancreatic fistula, defined as amylase-rich drain output of any
volume on or after post-operative day three in accordance with
the International Study Group on Pancreatic Fistula,18 was the
most common complication, occurring in nine (8%) patients
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overall. Haemorrhage occurred in eight patients (7%) and delayed
gastric emptying occurred in five patients (4%). Other complica-
tions included: abscess 8, wound infection 6, pulmonary embo-
lism 6, pneumonia 4, urinary tract infection 4, bowel obstruction
3, bacteraemia 2, bowel perforation 2, pneumothorax 1, parotidi-
tis 1, acute renal failure 1 and incisional hernia 1. No significant
differences were seen in complications based upon final lesion
histology. Seven patients (6%) died in the peri-operative period
with the highest mortality in patients with concomitant malig-
nancy (Table 1).
Benign vs. malignant cystic neoplasms
Descriptive statistics were calculated for several variables and are
shown in Table 2. The presence of symptoms was the most sensi-
tive variable for the presence of malignancy and had the greatest
negative predictive value. However, the presence of symptoms
alone was not predictive of malignancy given the low specificity
and positive predictive value. As a single variable, elevated CA19-9
was most specific for malignancy but was less sensitive than the
presence of symptoms or location of the lesion. Elevated CA19-9
had the highest positive likelihood ratio. In other words, when
CA19-9 levels measured greater than 35 U/ml there was a three-
fold greater chance that the lesion was malignant as compared
with benign lesions. Combining symptoms with elevated CA19-9
had the highest specificity (84%) and sensitivity (64%). The
overall positive likelihood ratio for these combined variables is
four, which suggests these pre-operative markers, when present,
increase the likelihood of malignancy four times relative to benign
lesions. Other combinations of clinical findings did not result in
meaningful improvements in sensitivity or specificity for malig-
nancy (Table 2).
Next, we utilized multivariate logistic regression to identify pre-
dictors of malignancy (Table 3). Increasing age, elevated CA19-9,
location within the head of pancreas and the presence of symp-
toms were significant in the univariate analysis. However, when
entered into the multivariate model, only elevated CA19-9 and
increasing size were predictive of harbouring a focus of pancreatic
adenocarcinoma.
Table 1 Clinical characteristics of all patients undergoing a pancreatectomy for cystic lesions of the pancreas based upon final tumour type
All Serous Mucinous Malignant P
n 114 33 46 35
Median age (range) 62 (24–84) 59 (38–83) 59 (24–83) 68 (36–84) 0.07
Female 74 (65%) 26 (78%) 28 (61%) 20 (57%) 0.13
Symptoms 90 (79%) 19 (5%) 40 (87%) 31 (89%) <0.01
Elevated CA19-9a 23 (37%) 1 (6%) 8 (36%) 14 (56%) <0.01
Head of pancreas 49 (43%) 8 (24%) 15 (33%) 26 (74%) <0.01
Median size (range) 4 cm (0.6–18.5) 3.5 cm (1.0–8.0) 3.6 cm (0.6–15.0) 4.5 cm (2.0–18.5) 0.11
Median length of stay (d) 9 7 9 11 0.03
Complications
Total 62 12 28 22
Patients 46 (40%) 9 (27%) 21 (46% 16 (46%) 0.29
Mortality 7 (6%) 1 (3%) 3 (6%) 3 (9%) 0.63
aCA19-9 data available for 62 patients (16 serous, 22 mucinous, 25 malignant).
Table 2 Descriptive statistics for predictors of malignancy
Variable Benign
(n = 79)
Malignant
(n = 35)
P-value Sens. Spec. PPV NPV LR+ LR-
Age mean (SD) 59.1 (13.2) 65 (12.4) 0.02 N/A N/A N/A N/A N/A N/A
Female 68% 57% 0.29 57% 32% 27% 63% 0.83 1.34
Symptoms 83% 94.3% 0.14 94% 25% 36% 91% 1.25 0.24
High CA19-9 (>35 mg/dl) 22% 67% 0.001 67% 78% 64% 80% 3.04 0.42
Head of the pancreas 29% 71% 0.001 71% 71% 52% 85% 2.45 0.41
Size cm Mean (SD) 4.1 (2.9) 5.6 (3.6) 0.04 N/A N/A N/A N/A N/A N/A
Symptoms & high CA19-9 64% 84% 0.0082 64% 84% 82% 61% 4 0.43
Symptoms & head of pancreas 56.9% 83% 0.03 57% 83% 49% 62% 3.35 0.52
High CA19-9 & head of pancreas 28% 70% <0.001 28% 70% 45% 83% 4.2 1.03
LR+, positive likelihood ratio; LR-, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
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Benign vs. premalignant or malignant cystic lesions
In order to identify predictors of premalignant or malignant cystic
neoplasms of the pancreas (i.e. those with clear indication for
resection), logistic regression analysis was undertaken in addition
to calculating positive and negative likelihood ratios (Table 4).
Male gender, increasing age, elevated CA19-9 and location of
the lesion within the head of the pancreas were all associated
with (pre)malignant histology. However, only male gender and
increasing size were predictive on multivariate analysis (Table 4).
CA19-9 as a predictor of malignancy and
premalignancy
We next sought to determine which of the continuous variables of
age, lesion size and CA19-9 would be the most accurate measure-
ment in determining the need for resection (i.e. mucinous with
and without malignancy). ROC curves were calculated for each of
the continuous variables using the dichotomous dependent vari-
able of serous vs. mucinous without associated cancer and serous
vs. mucinous with associated cancer (data not shown). The area
under the ROC curve (AUC) was calculated for each variable and
plotted in Fig. 1. An area of 0.5 is considered an inaccurate test
whereas an area of 1.0 is considered a perfect test.19,20 For prema-
lignant lesions (i.e. IPMN or MCN without associated cancer),
size was never a worthwhile test when considering all patients
together or stratifying for gender or lesion location (Fig. 1a). Simi-
larly, age was not a helpful test unless patients were men or had
lesions located in the head of the pancreas (AUC = 0.737 and
0.679, respectively). CA19-9, however, can be considered a fair test
for all patients regardless of gender or tumour location. When
considering all patients with cystic lesions that might be consid-
ered surgical candidates (i.e. those with premalignant mucinous
lesions or with cystic lesions harboring malignancy), size was
never accurate (Fig. 1b).Age was only helpful in men (AUC 0.660)
or for lesions located in the head of the pancreas (AUC 0.732).
CA19-9, however, was the best test with AUC > 0.7 for all patients
regardless of gender or lesion location.
Discussion
Cystic neoplasms of the pancreas are more frequently detected as
a result of improved resolution and quality of abdominal imaging
combined with a decreased threshold for obtaining these scans.
Many cystic lesions are malignant or have malignant potential.21,22
Determining which lesions require resection because of the risk of
developing or already harbouring malignancy is often perplexing
for the pancreatic surgeon, particularly for high risk or otherwise
asymptomatic patients. Despite the combination of advanced
Table 3 Logistic regression analysis of pre-operative clinical predic-
tors of malignancy
Variable Univariate
P-value
Multivariate
P-value
Male gender 0.25 N.S.
Age 0.03 N.S.
Location (head vs. body/tail) <0.001 N.S.
Elevated CA19-9 (>35 mg/dl) <0.001 <0.001
Size 0.19 0.025
Symptoms (present vs. absent) <0.001 N.S.
High CA19-9 & Head of Pancreas 0.143 N.S.
Table 4 Logistic regression analysis of pre-operative clinical predic-
tors of mucinous neoplasms of the pancreas with and without asso-
ciated malignancy
Variable Univariate
P-value
Multivariate
P-value
Male gender <0.001 <0.001
Age <0.001 N.S.
High CA19-9 0.018 N.S.
Location (head vs. body/tail) <0.001 N.S.
Size 0.2 <0.001
Symptoms (present vs. absent) 0.2 N.S.
A
All
Men
Women
Head
Body/Tail
0.2 0.3 0.4 0.5 0.6 0.7 0.8
Size
CA19–9
Age
All
Men
Women
Head
Body/Tail
0.2 0.3 0.4 0.5 0.6 0.7 0.8
Size
CA19–9
Age
B
Figure 1 Plot of area under the receiver-operating characteristic
(ROC) curves for continuous variables of size, carbohydrate antigen
(CA)19-9 and age to determine accuracy of each variable for pre-
dicting (a) benign mucinous cystic lesions of the pancreas and
(b) benign or malignant mucinous cystic lesions of the pancreas. A
value of 0.5 or less is consistent with a meaningless test
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imaging techniques and the utility of cyst fluid aspiration, it often
still remains a diagnostic dilemma for the surgeon as to which
cystic lesions of the pancreas require exptirpation.2,4 The role of
EUS and FNA is becoming clear as a valuable tool for predicting
lesions at risk.23,24 Unfortunately, EUS is not universally available
or feasible for all patients. We retrospectively reviewed our expe-
rience with the surgical management of cystic neoplasms of the
pancreas in order to identify predictors of malignancy or prema-
lignancy using universal clinical variables. Current literature on
cystic neoplasms of the pancreas varies from a close surveillance
approach in patients with asymptomatic, smaller lesions with no
suspicious features on imaging or FNA to a more aggressive sur-
gical approach, especially in patients with size > 3 cm.25,26
Our patients were divided into those with clearly benign lesions
without malignant potential (i.e. serous microcystic adenomas or
serous cystadenomas), those with premalignant lesions (i.e. IPMN
and MCN) and those with cystic lesions associated with invasive
ductal adenocarcinoma. As expected, patients with benign lesions
tended to be younger than those harbouring malignancy with a
female preponderance in those with SMAs. Serous lesions were
significantly more likely to be found incidentally, although
abdominal pain was still a common presentation. Elevations in
CA19-9 were rare in serous lesions whereas more than half of the
patients with malignancy demonstrated elevated CA19-9 levels.
Mucinous premalignant lesions were uncommonly found to have
elevated CA19-9 levels but were significantly more likely than
SMAs. Only one SMA presented with an elevated CA19-9 level.
Malignant tumors were significantly more likely to present with
lesions in the head of the pancreas than benign lesions. However,
this may reflect a selection bias as those who presented with asso-
ciated body or tail malignancies may have been less likely to be
selected for resection as a result of advanced disease. Still, others
have described the propensity for worrisome cystic lesions to
present in the head of the pancreas, and have advocated a more
aggressive approach to such lesions.27 Lesion size was not signifi-
cantly different between lesion types, although there was a trend
towards larger tumors harbouring malignancy. Finally, lesion type
did not significantly impact complication or mortality rates
although malignant lesions were associated with longer hospital
stays, perhaps as a result of three-quarters of the patients having
lesions located in the head of the pancreas and, thus, requiring a
pancreaticoduodenectomy.
To determine predictors of malignancy, we first chose to deter-
mine the sensitivity and specificity of gender, symptomatology,
elevated CA19-9 and tumor location as these are commonly
assessed at initial consultation. Although the sensitivity of symp-
toms as a variable for capturing malignant tumours was 94%,
specificity was quite low as was its PPV. This low PPV is of no
concern as once a patient presents with symptoms, they are likely
to be offered resection regardless of the risk of malignancy.
However, the absence of symptoms is a very important factor in
that 91% of patients with asymptomatic lesions did not harbour
malignancy. Normal CA19-9 levels and location in the body or tail
of the pancreas are also helpful determinants as they increase the
likelihood of finding a benign lesion. Combining these variables
did little to improve their descriptive characteristics.
Beyond descriptive characteristics associated with malignancy,
we utilized logistic regression to identify predictors of malignancy
using both univariate and multivariate analysis. Although several
variables studied show a favourable trend in predicting malig-
nancy using univariate analysis, only elevated CA19-9 and
increasing tumour size were statistically significant using multi-
variate analysis. Still, given our interest in determining indicators
for resection, not merely malignancy alone, to assist in the
decision-making process at the time of initial consultation, we
grouped premalignant and malignant lesions together to identify
clinical predictors. Multivariate logistic regression analysis in this
group identified male gender and increasing lesion size as signifi-
cant predictors.
Lesion size has been suggested to be an invaluable determi-
nant of the risk of (pre)malignancy with most consensus sug-
gesting 3 cm as the cut-off for resection of asymptomatic
lesions.28,29 Indeed, using ROC curve analysis, we found 3 cm to
be the size at which we were able to obtain the highest sensitivity
and specificity (data not shown). Worrisome is that three cancers
and 18 premalignant mucinous lesions under 3 cm in size were
found in our data set. None of the cancers and only three of the
mucinous lesions, however, were asymptomatic. Therefore, it
could certainly be argued that, with surveillance, no occult
cancers would be missed with a threshold of 3 cm. A recent large
multi-institutional study concluded that malignancy in cystic
neoplasms 3 cm in size or less was associated with older age,
male gender, presence of symptoms and concerning radiographi-
cal features.30 Among the asymptomatic patients without con-
cerning radiographical features who underwent resection, the
incidence of occult malignancy was 3.3%. However, in our series
20 serous lesions were greater than 3 cm in size; half of which
were asymptomatic. Arguably, these patients could have been
spared the morbidity of a pancreatectomy with more accurate
pre-operative testing.
We attempted to identify which non-invasive clinical character-
istic would be most accurate at determining malignancy and/or
premalignancy. The area under the ROC curves and likelihood
ratios were utilized to determine the general accuracy of the con-
tinuous variables of age, CA19-9 and lesion size. Interestingly, size
failed to accurately predict malignancy or premalignancy regard-
less of gender or lesion location. Conversely, CA19-9 proved to be
at least a reasonable test at predicting premalignancy and a good
test at accurately predicting mucinous lesions with or without
malignancy. Thus, CA19-9 was the most helpful test in determin-
ing who would potentially benefit from a pancreatectomy, espe-
cially when combined with presentation of symptoms or location
of the tumour in the head of the pancreas. Age, while not univer-
sally accurate, proved to be helpful in identifying men with pre-
malignant lesions and patients with malignant/ premalignant
lesions in the head of the pancreas.
668 HPB
HPB 2009, 11, 664–670 © 2009 International Hepato-Pancreato-Biliary Association
It is important to recognize that only the patients selected for
resection are included in this study. In general, patients were
selected for resection based upon the presence of symptoms, the
size (or change in size) of the lesion, or worrisome appearance of
the lesion on radiographical imaging. It is certainly possible that
the rationale for resection was subjective based upon surgeon
experience or other factors that were unable to be ascertained in
this retrospective review. What is not known from our data set is
the prevalence of cystic neoplasms of the pancreas. In other words,
we are unable to make definitive conclusions about the aforemen-
tioned tests relative to the entire cohort of patients including those
who were not selected for resection or,more likely, were never sent
for surgical opinion.While in itself this is an obvious weakness of
this study, we believe that this patient population represents the
typical patient that pancreatic surgeons commonly see and con-
sider for surgical intervention. As such, the data herein may be
helpful when counselling patients where the benefit of resection is
unclear.
In conclusion, although our data suggest that premalignant and
malignant cystic neoplasms of the pancreas are associated with
larger lesions, size alone is not an accurate means for determining
need for a pancreatectomy. Instead, we suggest that CA19-9 is the
most universally accurate non-invasive test to determine who is at
risk of having a premalignant or malignant cystic neoplasm of the
pancreas. We recommend that patients with incidentally found
cystic lesions and an elevated serum CA19-9 be considered for
surgical resection, regardless of lesion size.
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